New analytical tools and technologies have become a major part of modern medicine, saving lives through a combination of early problem detection and a growing understanding of how the human body operates. Advanced genetics is now playing an increasingly important … Continue reading →

Cardiovascular disease is responsible for 17 million deaths around the globe, making it the No. 1 cause of death worldwide, according to the American Heart Association and the World Health Organization. The disease is often onset by poor lifestyle choices, … Continue reading →

Cardium Therapeutics recently announced that its wholly-owned subsidiary, LifeAgain™ Insurance Solutions Inc., has entered into a commercialization agreement with AgencyONE. The agreement will have LifeAgain™ supporting the development and commercialization of innovative, survivable risk life insurance products based on Cardium’s … Continue reading →

Cardium Therapeutics today presented recent highlights and other business developments while reporting its financial results for the second quarter ended June 30, 2013. The company said it now has four business units in its portfolio: Angionetics Biologics, which includes Cardium’s … Continue reading →

Cardium Therapeutics, a health sciences and regenerative medicine company, today announced its research collaboration with researchers at Boston Children’s Hospital to assess the medical utility of Cardium’s Excellagen® to repair prenatally diagnosed birth defects using mesenchymal fetal stem cells for … Continue reading →

Today before the opening bell, Cardium Therapeutics announced that it has entered into a distribution agreement with Kasiak Holdings AG for the marketing and sale of Excellagen® advanced wound care product in Germany and Switzerland. Kasiak Holdings is affiliated with … Continue reading →

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, has signed an agreement with Orbsen Therapeutics Ltd. and the National University of Ireland, Galway, to utilize Cardium’s FDA-cleared Excellagen® gel as a delivery agent for Orbsen’s proprietary stromal cell … Continue reading →

Earlier today Cardium Therapeutics, an asset-based, health sciences and regenerative medicine company, announced the filing of a new 510(k) submission for its current FDA-cleared Excellagen® advanced wound care product. The filing reflects additional and specific structural and functional properties of … Continue reading →

Today before the open, Cardium Therapeutics announced that it has signed a distribution agreement with AvKARE encompassing government medical facilities throughout the United States. The new commercialization arrangement with AvKARE effectively replaces an earlier arrangement with Academy Medical. Cardium chose … Continue reading →

The financial front has been especially active for Cardium Therapeutics over the past few weeks. The San Diego based health sciences and regenerative medicine company finalized and executed a reverse stock split, a condition of an earlier securities purchase agreement, … Continue reading →